ATXS

ATXS

USD

Astria Therapeutics Inc. Common Stock

$12.250+0.120 (0.989%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$12.130

High

$12.390

Low

$12.110

Volume

1.43M

Company Fundamentals

Market Cap

691.3M

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

1.58M

Exchange

NGM

Currency

USD

52-Week Range

Low $3.555Current $12.250High $12.715

Related News

BusinessWire

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present final results from the

View more
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
PR Newswire

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HOLX, TRUE, PCH, ATXS on Behalf of Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

View more
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HOLX, TRUE, PCH, ATXS on Behalf of Shareholders
Analyst Upgrades

JMP Securities Downgrades Astria Therapeutics to Market Perform

JMP Securities analyst Jonathan Wolleben downgrades Astria Therapeutics from Market Outperform to Market Perform.

View more
JMP Securities Downgrades Astria Therapeutics to Market Perform
PR Newswire

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS)

Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for...

View more
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS)
Analyst Upgrades

Jefferies Downgrades Astria Therapeutics to Hold, Lowers Price Target to $13

Jefferies analyst Eun Yang downgrades Astria Therapeutics from Buy to Hold and lowers the price target from $30 to $13.

View more
Jefferies Downgrades Astria Therapeutics to Hold, Lowers Price Target to $13
PR Newswire

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ATXS, PCH, RYN on Behalf of Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

PR Newswire

Shareholder Alert: The Ademi Firm investigates whether Astria Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

The Ademi Firm is investigating Astria (NASDAQ: ATXS) for possible breaches of fiduciary duty and other violations of law in its transaction with...